ArticleParasites & vectors2026
Efficacy and safety of a sustained-release formulation of ivermectin (FILAPREV®) in preventing heartworm infection (Dirofilaria immitis) in dogs in two endemic areas of Italy.
Article in Parasites & vectors, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMacrocyclic lactones are the only drug class currently licensed for heartworm disease prophylaxis. Macrocyclic lactones kill third- and fourth-stage larvae of the parasitic nematode Dirofilaria immitis, thus preventing the development of adult worms in dogs, which are responsible for heartworm disease, a potentially life-threatening condition. The objective of the present study was to assess the efficacy of a subcutaneous implant formulation containing ivermectin (FILAPREV®; Ceva Santé Animale, Libourne, France) compared to extended-release moxidectin (Guardian™ SR; Elanco, Indianapolis, IN, USA) to protect dogs against D. immitis infection during the entire transmission-risk season in Italy, starting in April and ending in November.
methodsA total of 114 healthy client-owned dogs were enrolled at two investigation sites located in two different regions of Italy known to be endemic for D. immitis (Lombardy and Veneto). In the spring of 2017, approximately half of the dogs from each site randomly received a single dose of FILAPREV® (ivermectin, 0.13 mg/kg as minimum standard dose); the remaining dogs were treated with a single dose of Guardian™ SR (moxidectin, 0.17 mg/kg). Antigen and Knott's tests were performed before treatment, and subsequently at 1 week and 6, 8 and 12 months post-treatment. Clinical examination, thoracic radiography and echocardiography were conducted at the same time points.
resultsOf the 114 dogs enrolled in the study, 112 completed the entire study period. No adverse reactions were observed, and all dogs enrolled in the study remained heartworm-negative throughout the entire study period.
conclusionsA single subcutaneous administration of FILAPREV®, an implant containing ivermectin at the recommended dosage, prevents heartworm disease caused by D. immitis in dogs for at least 8 months, covering the full seasonal period of heartworm transmission in hyperendemic regions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.